NU2058 was first identified as a guanine‐based cyclin‐dependent kinase (CDK) (CDK1/CDK2) inhibitor.[6] Interestingly, NU2058 was also reported to exert a CDK2‐independent effect on cancer chemoresistance.[7] To date, the anticancer bioactivity of NU2058 in CRC and the underlying mechanism have not been reported. This evidence concerns the gene CDK2 and colorectal carcinoma.